

## Annual report on the liquidity contract with Gilbert Dupont

Market: Euronext Paris  
ISIN code / Mnemo: CH0308403085 / GNRO  
Web site: [www.geneuro.com](http://www.geneuro.com)

Pursuant to the liquidity contract entrusted by GENEURO SA to Gilbert Dupont, as of December 31, 2017, the following assets appeared on the liquidity account:

- Number of shares: 37,532
- Cash balance of the liquidity account: € 352,681.84

As a reminder, as of June 30, 2017, the following resources were booked to the liquidity account:

- Number of shares: 33,678
- Cash balance of the liquidity account: €284,643.00

### About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis or Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 31 employees and rights to 16 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

### Contacts

GeNeuro	NewCap (France)	Halsin Partners	LifeSci Advisors
Jesús Martin-Garcia	Julien Perez (investors)	Mike Sinclair (media)	Chris Maggos (investors)
Chairman and CEO	+33 1 44 71 98 52	+44 20 7318 2955	+1 646 597 6970
+41 22 552 4800	Nicolas Merigeau (media)	<a href="mailto:msinclair@halsin.com">msinclair@halsin.com</a>	+41 79 367 6254
<a href="mailto:investors@geneuro.com">investors@geneuro.com</a>	+33 1 44 71 94 98		<a href="mailto:chris@lifesciadvisors.com">chris@lifesciadvisors.com</a>
	<a href="mailto:geneuro@newcap.eu">geneuro@newcap.eu</a>		